John D. Carpten
Director, Institute of Translational Genomics
Royce and Mary Trotter Chair in Cancer Research
Contact
National Institutes of Health: NIH/NHGRI Jeffrey M. Trent Lectureship, 2016-2016
Susan G. Komen for the Cure: AACR Distinguished Lectureship on the Science of Health Disparities, 2014-2014
Science Spectrum Magazine: Science Trailblazer, 2006-2006
National Institutes of Health: NHGRI Faculty Mentor Awardee , 2002-2002
National Institutes of Health: NHGRI Faculty Mentor Awardee, 2002-2002
Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry Eur Urol. 2023 Feb 27. . View in PubMed
Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations JCO Precis Oncol. 2023 01; 7:e2200300. . View in PubMed
Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network Cancer Epidemiol Biomarkers Prev. 2023 04 03; 32(4):487-495. . View in PubMed
Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma PLoS One. 2023; 18(4):e0284949. . View in PubMed
Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer Cancer Res. 2023 01 04; 83(1):34-48. . View in PubMed
Results and lessons from dual extraction of DNA and RNA from formalin-fixed paraffin-embedded breast tumor tissues for a large Cancer epidemiologic study BMC Genomics. 2022 Aug 25; 23(1):614. . View in PubMed
Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer Cancer Causes Control. 2022 Jun; 33(6):831-841. . View in PubMed
A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry Eur Urol. 2022 05; 81(5):458-462. . View in PubMed
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial Mol Oncol. 2022 01; 16(1):104-115. . View in PubMed
Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials Ethn Dis. 2022 Winter; 32(1):61-68. . View in PubMed
African Ancestry-Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent Cancer Discov. 2022 11 02; 12(11):2530-2551. . View in PubMed
Correction: Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients Oncogene. 2021 Nov; 40(45):6394. . View in PubMed
Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study JMIR Cancer. 2021 Sep 23; 7(3):e25621. . View in PubMed
Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry Breast Cancer Res Treat. 2021 Apr; 186(2):391-401. . View in PubMed
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction Nat Genet. 2021 Mar; 53(3):413. . View in PubMed
Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients Oncogene. 2021 11; 40(45):6329-6342. . View in PubMed
Making cancer research more inclusive Nat Rev Cancer. 2021 10; 21(10):613-618. . View in PubMed
Developing a Novel Framework for an Undergraduate Cancer Research Education and Engagement Program for Underrepresented Minority Students: the Florida-California CaRE2 Research Education Core (REC) Training Program J Cancer Educ. 2021 10; 36(5):914-919. . View in PubMed
Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer Eur Urol. 2021 03; 79(3):353-361. . View in PubMed
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction Nat Genet. 2021 01; 53(1):65-75. . View in PubMed
Applicability of spatial transcriptional profiling to cancer research Mol Cell. 2021 04 15; 81(8):1631-1639. . View in PubMed
Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas Genes (Basel). 2021 09 11; 12(9). . View in PubMed
Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry Am J Hum Genet. 2021 04 01; 108(4):564-582. . View in PubMed
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial PLoS One. 2021; 16(4):e0248097. . View in PubMed
Patterns of Early-Onset Colorectal Cancer Among Nigerians and African Americans JCO Glob Oncol. 2020 10; 6:1647-1655. . View in PubMed
A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry Eur Urol. 2020 09; 78(3):316-320. . View in PubMed
Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma J Med Chem. 2020 10 22; 63(20):11484-11497. . View in PubMed
Single-cell sequencing of genomic DNA resolves sub-clonal heterogeneity in a melanoma cell line Commun Biol. 2020 06 25; 3(1):318. . View in PubMed
Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa078. . View in PubMed
Cancer transcriptomic profiling from rapidly enriched circulating tumor cells Int J Cancer. 2020 05 15; 146(10):2845-2854. . View in PubMed
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry Blood Adv. 2020 01 14; 4(1):181-190. . View in PubMed
Pathology Services in Nigeria: Cross-Sectional Survey Results From Three Cancer Consortia J Glob Oncol. 2019 09; 5:1-9. . View in PubMed
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases Invest New Drugs. 2019 08; 37(4):636-645. . View in PubMed
Histological Validation of 11Carbon-Acetate Positron Emission Tomography/Computerized Tomography in Detecting Lymph Node Metastases in Prostate Cancer J Urol. 2019 02; 201(2):332-341. . View in PubMed
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer Sci Rep. 2019 02 06; 9(1):1482. . View in PubMed
Multiparametric liquid biopsy analysis in metastatic prostate cancer JCI Insight. 2019 03 07; 4(5). . View in PubMed
Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells Mol Oncol. 2018 06; 12(7):1138-1152. . View in PubMed
Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans Carcinogenesis. 2018 12 13; 39(11):1331-1341. . View in PubMed
Integrating the Genetics of Race and Ethnicity Into Cancer Research: Trailing Jane and John QPublic. JAMA Surg. 2018 04 01; 153(4):299-300. . View in PubMed
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma Clin Cancer Res. 2018 01 15; 24(2):295-305. . View in PubMed
Profiling targetable immune checkpoints in osteosarcoma Oncoimmunology. 2018; 7(12):e1475873. . View in PubMed
Mitochondrial biology and prostate cancer ethnic disparity Carcinogenesis. 2018 12 13; 39(11):1311-1319. . View in PubMed
Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum Oncotarget. 2017 Nov 21; 8(59):99237-99244. . View in PubMed
Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases PLoS Genet. 2017 Nov; 13(11):e1007087. . View in PubMed
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer Clin Cancer Res. 2017 Aug 15; 23(16):4919-4928. . View in PubMed
Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium PLoS Genet. 2017 Apr; 13(4):e1006719. . View in PubMed
Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series BJU Int. 2017 09; 120(3):401-408. . View in PubMed
Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib Clin Genitourin Cancer. 2017 08; 15(4):e727-e734. . View in PubMed
gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels Genet Epidemiol. 2017 05; 41(4):297-308. . View in PubMed
Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma Genome Res. 2017 04; 27(4):524-532. . View in PubMed
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML Clin Epigenetics. 2017; 9:108. . View in PubMed
Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry J Natl Cancer Inst. 2017 08 01; 109(8). . View in PubMed
Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies BMC Cancer. 2017 01 05; 17(1):17. . View in PubMed
Identifying aggressive prostate cancer foci using a DNA methylation classifier Genome Biol. 2017 01 12; 18(1):3. . View in PubMed
A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy PLoS One. 2017; 12(6):e0179170. . View in PubMed
A method to reduce ancestry related germline false positives in tumor only somatic variant calling BMC Med Genomics. 2017 10 19; 10(1):61. . View in PubMed
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants Am J Hum Genet. 2016 Oct 06; 99(4):877-885. . View in PubMed
Prostate Cancer Susceptibility in Men of African Ancestry at 8q24 J Natl Cancer Inst. 2016 Jul; 108(7). . View in PubMed
Translating RNA sequencing into clinical diagnostics: opportunities and challenges Nat Rev Genet. 2016 May; 17(5):257-71. . View in PubMed
A somatic reference standard for cancer genome sequencing Sci Rep. 2016 Apr 20; 6:24607. . View in PubMed
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation Nat Commun. 2016 Apr 07; 7:10979. . View in PubMed
Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation Pediatr Blood Cancer. 2016 Apr; 63(4):727-30. . View in PubMed
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. . View in PubMed
Molecular Genetic Profiling of Adolescent Glassy Cell Carcinoma of the Cervix Reveals Targetable EGFR Amplification with Potential Therapeutic Implications J Adolesc Young Adult Oncol. 2016 09; 5(3):297-302. . View in PubMed
Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies Genet Epidemiol. 2016 09; 40(6):461-9. . View in PubMed
Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers Sci Rep. 2016 12 23; 6(1):25. . View in PubMed
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions Hum Mol Genet. 2015 Oct 01; 24(19):5603-18. . View in PubMed
Toward precision medicine in glioblastoma: the promise and the challenges Neuro Oncol. 2015 Aug; 17(8):1051-63. . View in PubMed
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team Mol Cancer Ther. 2015 Aug; 14(8):1962-71. . View in PubMed
Novel pathogenic variants and genes for myopathies identified by whole exome sequencing Mol Genet Genomic Med. 2015 Jul; 3(4):283-301. . View in PubMed
Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias Invest New Drugs. 2015 Apr; 33(2):389-96. . View in PubMed
Generalizability of established prostate cancer risk variants in men of African ancestry Int J Cancer. 2015 Mar 01; 136(5):1210-7. . View in PubMed
Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion Mol Genet Genomic Med. 2015 Mar; 3(2):130-6. . View in PubMed
Methodological Considerations in Estimation of Phenotype Heritability Using Genome-Wide SNP Data, Illustrated by an Analysis of the Heritability of Height in a Large Sample of African Ancestry Adults PLoS One. 2015; 10(6):e0131106. . View in PubMed
An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine Pac Symp Biocomput. 2015; 56-67. . View in PubMed
8q24 risk alleles and prostate cancer in African-Barbadian men Prostate. 2014 Dec; 74(16):1579-88. . View in PubMed
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer Nat Genet. 2014 Oct; 46(10):1103-9. . View in PubMed
Open-access synthetic spike-in mRNA-seq data for cancer gene fusions BMC Genomics. 2014 Sep 30; 15:824. . View in PubMed
Detection of an atypical teratoid rhabdoid brain tumor gene deletion in circulating blood using next-generation sequencing J Child Neurol. 2014 Sep; 29(9):NP81-5. . View in PubMed
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer BMC Med Genomics. 2014 Jun 18; 7:36. . View in PubMed
Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer Prostate. 2014 Jun; 74(9):983-90. . View in PubMed
Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target World J Surg. 2014 Jun; 38(6):1296-305. . View in PubMed
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease Hum Genet. 2014 Mar; 133(3):347-56. . View in PubMed
Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing Int J Gynecol Cancer. 2014 Feb; 24(2):329-38. . View in PubMed
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma PLoS Genet. 2014 Feb; 10(2):e1004135. . View in PubMed
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements PLoS One. 2014; 9(2):e87113. . View in PubMed
Integrated genomic and epigenomic analysis of breast cancer brain metastasis PLoS One. 2014; 9(1):e85448. . View in PubMed
Long insert whole genome sequencing for copy number variant and translocation detection Nucleic Acids Res. 2014 Jan; 42(2):e8. . View in PubMed
Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma Haematologica. 2013 Oct; 98(10):1586-92. . View in PubMed
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease Br J Haematol. 2013 Jun; 161(5):748-751. . View in PubMed
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry Nat Genet. 2013 Jun; 45(6):690-6. . View in PubMed
Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma Cancer Metab. 2013 May 29; 1(1):14. . View in PubMed
Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs BMC Genomics. 2013 May 04; 14:302. . View in PubMed
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach Blood. 2013 Apr 18; 121(16):3147-52. . View in PubMed
CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma Cancer Res. 2013 Apr 01; 73(7):2044-51. . View in PubMed
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities Mol Cancer Ther. 2013 Jan; 12(1):104-16. . View in PubMed
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) Hum Genet. 2013 Jan; 132(1):5-14. . View in PubMed
A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges PLoS One. 2013; 8(10):e76438. . View in PubMed
Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer Fam Cancer. 2012 Dec; 11(4):595-600. . View in PubMed
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing Sci Transl Med. 2012 Nov 28; 4(162):162ra154. . View in PubMed
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides Blood. 2012 Aug 02; 120(5):1060-6. . View in PubMed
Clonal competition with alternating dominance in multiple myeloma Blood. 2012 Aug 02; 120(5):1067-76. . View in PubMed
Differential effects of AKT1(pE17K) expression on human mammary luminal epithelial and myoepithelial cells. Hum Mutat. 2012 Aug; 33(8):1216-27. . View in PubMed
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families BMC Med Genet. 2012 Jun 19; 13:46. . View in PubMed
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG Prostate. 2012 Mar; 72(4):410-26. . View in PubMed
Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses Prostate. 2012 Mar; 72(4):376-85. . View in PubMed
Germline mutations in HOXB13 and prostate-cancer risk N Engl J Med. 2012 Jan 12; 366(2):141-9. . View in PubMed
Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma PLoS One. 2012; 7(5):e37029. . View in PubMed
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing PLoS One. 2012; 7(10):e43192. . View in PubMed
Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability Genome Med. 2012; 4(7):56. . View in PubMed
Deep clonal profiling of formalin fixed paraffin embedded clinical samples PLoS One. 2012; 7(11):e50586. . View in PubMed
DNA methylation in multiple myeloma is weakly associated with gene transcription PLoS One. 2012; 7(12):e52626. . View in PubMed
Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology BMC Womens Health. 2011 Sep 30; 11:44. . View in PubMed
Advancing a clinically relevant perspective of the clonal nature of cancer Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):12054-9. . View in PubMed
Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer Carcinogenesis. 2011 Jul; 32(7):1057-62. . View in PubMed
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21 Nat Genet. 2011 Jun; 43(6):570-3. . View in PubMed
Initial genome sequencing and analysis of multiple myeloma Nature. 2011 Mar 24; 471(7339):467-72. . View in PubMed
Next-generation sequencing of Coccidioides immitis isolated during cluster investigation Emerg Infect Dis. 2011 Feb; 17(2):227-32. . View in PubMed
EphB2 SNPs and sporadic prostate cancer risk in African American men PLoS One. 2011; 6(5):e19494. . View in PubMed
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors Genome Res. 2011 Jan; 21(1):47-55. . View in PubMed
Racial disparities in prostate cancer incidence, biochemical recurrence, and mortality Prostate Cancer. 2011; 2011:716178. . View in PubMed
Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population Prostate. 2010 Nov 01; 70(15):1716-27. . View in PubMed
DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors Cancer Res. 2010 Sep 01; 70(17):6934-44. . View in PubMed
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses Prostate. 2010 May 15; 70(7):735-44. . View in PubMed
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma Leukemia. 2010 Apr; 24(4):833-42. . View in PubMed
Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans Prostate. 2010 Feb 15; 70(3):270-5. . View in PubMed
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2136-40. . View in PubMed
Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples Nucleic Acids Res. 2010 Jan; 38(2):e9. . View in PubMed
Two independent prostate cancer risk-associated Loci at 11q13 Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1815-20. . View in PubMed
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia Cancer Res. 2009 Apr 15; 69(8):3579-88. . View in PubMed
A novel prostate cancer susceptibility locus at 19q13 Cancer Res. 2009 Apr 01; 69(7):2720-3. . View in PubMed
Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk Hum Mol Genet. 2009 Apr 01; 18(7):1368-75. . View in PubMed
Association of a germ-line copy number variation at 2p243 and risk for aggressive prostate cancer. Cancer Res. 2009 Mar 15; 69(6):2176-9. . View in PubMed
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer Prostate. 2009 Mar 01; 69(4):419-27. . View in PubMed
Genetic variants and family history predict prostate cancer similar to prostate-specific antigen Clin Cancer Res. 2009 Feb 01; 15(3):1105-11. . View in PubMed
Sequence variants at 22q13 are associated with prostate cancer risk Cancer Res. 2009 Jan 01; 69(1):10-5. . View in PubMed
Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases Prostate. 2008 Dec 01; 68(16):1790-7. . View in PubMed
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12 Nat Genet. 2008 Oct; 40(10):1153-5. . View in PubMed
Family-based samples can play an important role in genetic association studies Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2208-14. . View in PubMed
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations Prostate. 2008 Sep 01; 68(12):1257-62. . View in PubMed
Association between sequence variants at 17q12 and 17q243 and prostate cancer risk in European and African Americans. Prostate. 2008 May 15; 68(7):691-7. . View in PubMed
Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients Prostate. 2008 Apr 01; 68(5):489-97. . View in PubMed
Cumulative association of five genetic variants with prostate cancer N Engl J Med. 2008 Feb 28; 358(9):910-9. . View in PubMed
PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation Br J Haematol. 2008 Feb; 140(3):344-7. . View in PubMed
Admixture and population stratification in African Caribbean populations Ann Hum Genet. 2008 Jan; 72(Pt 1):90-8. . View in PubMed
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP J Natl Cancer Inst. 2007 Dec 19; 99(24):1836-44. . View in PubMed
Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus Genome Res. 2007 Dec; 17(12):1717-22. . View in PubMed
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans J Natl Cancer Inst. 2007 Oct 17; 99(20):1525-33. . View in PubMed
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma Cancer Cell. 2007 Aug; 12(2):131-44. . View in PubMed
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature. 2007 Jul 26; 448(7152):439-44. . View in PubMed
Compelling evidence for a prostate cancer gene at 22q123 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet. 2007 Jun 01; 16(11):1271-8. . View in PubMed
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling Cancer Res. 2007 Apr 01; 67(7):2982-9. . View in PubMed
Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis Hum Genet. 2007 Mar; 121(1):49-55. . View in PubMed
Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC) Prostate. 2007 Jan 01; 67(1):22-31. . View in PubMed
A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study Prostate. 2006 Oct 01; 66(14):1556-64. . View in PubMed
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history J Med Genet. 2006 Jun; 43(6):507-11. . View in PubMed
Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27 Genome Res. 2005 Nov; 15(11):1477-86. . View in PubMed
A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region Hum Genet. 2005 Aug; 117(4):307-16. . View in PubMed
Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer Cancer Lett. 2005 Mar 10; 219(2):177-82. . View in PubMed
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth J Clin Invest. 2005 Mar; 115(3):622-31. . View in PubMed
Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome J Intern Med. 2005 Jan; 257(1):18-26. . View in PubMed
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer Nat Genet. 2004 Sep; 36(9):979-83. . View in PubMed
Combined genome-wide scan for prostate cancer susceptibility genes J Natl Cancer Inst. 2004 Aug 18; 96(16):1240-7. . View in PubMed
Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP) J Med Genet. 2004 Mar; 41(3):e32. . View in PubMed
Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer Genes Chromosomes Cancer. 2004 Feb; 39(2):119-25. . View in PubMed
Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study Prostate Cancer Prostatic Dis. 2004; 7(2):165-9. . View in PubMed
Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome J Clin Endocrinol Metab. 2004 Jan; 89(1):96-102. . View in PubMed
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma N Engl J Med. 2003 Oct 30; 349(18):1722-9. . View in PubMed
Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates Cancer Res. 2003 Oct 15; 63(20):6795-801. . View in PubMed
Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study Mutat Res. 2003 Jul 25; 528(1-2):45-53. . View in PubMed
Hyperparathyroidism-jaw tumour syndrome J Intern Med. 2003 Jun; 253(6):634-42. . View in PubMed
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer Am J Hum Genet. 2002 May; 70(5):1299-304. . View in PubMed
Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility Cancer Res. 2002 Mar 15; 62(6):1784-9. . View in PubMed
Identification of six novel genes by experimental validation of GeneMachine predicted genes Gene. 2002 Feb 06; 284(1-2):203-13. . View in PubMed
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 Nat Genet. 2002 Feb; 30(2):181-4. . View in PubMed
Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk Hum Genet. 2002 Feb; 110(2):122-9. . View in PubMed
Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile Cancer Res. 2001 Dec 15; 61(24):8624-8. . View in PubMed
African-American heredity prostate cancer study: a model for genetic research J Natl Med Assoc. 2001 Dec; 93(12 Suppl):25S-28S. . View in PubMed
Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23 Am J Hum Genet. 2001 Aug; 69(2):341-50. . View in PubMed
Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus Genomics. 2001 Apr 15; 73(2):211-22. . View in PubMed
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer Am J Hum Genet. 2001 Apr; 68(4):901-11. . View in PubMed
African-American heredity prostate cancer study: a model for genetic research J Natl Med Assoc. 2001 Apr; 93(4):120-3. . View in PubMed
Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in US. pedigrees. J Lipid Res. 2001 Feb; 42(2):159-69. . View in PubMed
Report and abstracts of the sixth international workshop on human chromosome 1 mapping 2000Iowa City, Iowa, USA. 30 September-3 October 2000. Cytogenet Cell Genet. 2001; 92(1-2):23-41. . View in PubMed
Prostate cancer susceptibility genes: many studies, many results, no answers Cancer Metastasis Rev. 2001; 20(3-4):155-64. . View in PubMed
A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease Clin Cancer Res. 2000 Dec; 6(12):4810-5. . View in PubMed
Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study Ann Epidemiol. 2000 Nov; 10(8 Suppl):S68-77. . View in PubMed
Molecular classification of cutaneous malignant melanoma by gene expression profiling Nature. 2000 Aug 03; 406(6795):536-40. . View in PubMed
The human RGL (RalGDS-like) gene: cloning, expression analysis and genomic organization Biochim Biophys Acta. 2000 Apr 25; 1491(1-3):285-8. . View in PubMed
A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region Genomics. 2000 Feb 15; 64(1):1-14. . View in PubMed
Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q422-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet. 2000 Feb; 66(2):539-46. . View in PubMed
CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome Nat Genet. 1999 Nov; 23(3):319-22. . View in PubMed
In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer Am J Hum Genet. 1999 Jul; 65(1):134-40. . View in PubMed
Evidence for a prostate cancer susceptibility locus on the X chromosome Nat Genet. 1998 Oct; 20(2):175-9. . View in PubMed
Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1 Cancer Res. 1997 Nov 01; 57(21):4707-9. . View in PubMed
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus JAMA. 1997 Oct 15; 278(15):1251-5. . View in PubMed
Methods for precise sizing, automated binning of alleles, and reduction of error rates in large-scale genotyping using fluorescently labeled dinucleotide markersFUSION (Finland-U. S. Investigation of NIDDM Genetics) Study Group. Genome Res. 1997 Feb; 7(2):165-78. . View in PubMed
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search Science. 1996 Nov 22; 274(5291):1371-4. . View in PubMed
Modulation of non-templated nucleotide addition by Taq DNA polymerase: primer modifications that facilitate genotyping Biotechniques. 1996 Jun; 20(6):1004-61008-10. . View in PubMed
Approach to genotyping errors caused by nontemplated nucleotide addition by Taq DNA polymerase Genome Res. 1995 Oct; 5(3):312-7. . View in PubMed
Refined physical map of the spinal muscular atrophy gene (SMA) region at 5q13 based on YAC and cosmid contiguous arrays Genomics. 1995 Apr 10; 26(3):451-60. . View in PubMed
Association between Ag1-CA alleles and severity of autosomal recessive proximal spinal muscular atrophy Am J Hum Genet. 1994 Dec; 55(6):1218-29. . View in PubMed
A YAC contig of the region containing the spinal muscular atrophy gene (SMA): identification of an unstable region Genomics. 1994 Nov 15; 24(2):351-6. . View in PubMed
A multicopy dinucleotide marker that maps close to the spinal muscular atrophy gene Genomics. 1994 May 15; 21(2):394-402. . View in PubMed
Linkage mapping of the spinal muscular atrophy gene Hum Genet. 1994 Mar; 93(3):305-12. . View in PubMed
Dr. Carpten earned his Ph.D. from the Ohio State University in 1994 with a focus on human genetics. He then went on to complete a postdoctoral fellowship at the National Human Genome Research Institute, NIH, Bethesda, in Cancer Genetics, where he was later promoted to the tenure track in 2000. Then in 2003, Dr. Carpten accepted a position to become Division Director, Division of Integrated Cancer Genomics, at the Translational Genomics Research Institute (TGen), Phoenix, AZ. Later, in 2012 he was promoted to the position of Deputy Director of Basic Research for TGen. In 2016 he was recruited by the University of Southern California Keck School of Medicine, to build and chair a new Department and Institute of Translational Genomics.
Dr. Carpten’s primary research program centers around the development and application of cutting edge genomic technologies and bioinformatics analysis in search of germ-line and somatic alterations that are associated with cancer risk and tumor characteristics, respectively. A major focus of Dr. Carpten’s research has been related to prostate cancer genetics. He was a lead author on the first genome wide scan for hereditary prostate cancer genes (Science. 1996 Nov 22;274(5291):1371-4.), and the identification of HOXB13 as the first true hereditary prostate cancer gene (New England Journal of Medicine. 2012 Jan 12;366(2):141-9.). His group has also discovered a number of single nucleotide polymorphisms, which confer increased risk of developing prostate cancer (Journal of the National Cancer Institute. 2007 Dec 19;99(24):1836-44.). Furthermore, he has played a critical role in prostate cancer cell biology studies (Nat Genet. 2004 Sep;36(9):979-83.), and prostate cancer tumor genome profiling studies (Genome Res. 2011 Jan;21(1):47-55.).
Dr. Carpten has also been an early pioneer in the understanding the role of biology in disparate cancer incidence and mortality rates seem among underrepresented populations. Through his leadership, the African American Hereditary Prostate Cancer Study (AAHPC) Network was conceived. This study has become a model for genetic linkage studies in underrepresented populations and led to the first genome wide scan for prostate cancer susceptibility genes in African Americans (Prostate. 2007 Jan 1;67(1):22-31.).
Dr. Carpten’ cancer research program spans many tumor types including but not limited to prostate cancer, breast cancer, colon cancer, brain cancer, and multiple myeloma, in addition to several forms of pediatric cancer. He led a landmark study, which culminated in the discovery of the AKT1(E17K) activating mutation in human cancers, published in Nature. This study received an Exceptional rating by the Faculty of 1000, placing the paper in the top 1% of published work worldwide in the area of biology in 2007. It also received a “Must Read” rating, placing the paper in the top 5% of published work in the area of medicine. He extended this work to include an in depth analysis of the functional and mechanistic effects of this mutation on mammary cell biology (Human Mutation). Furthermore, his laboratory participated in and led several high impact studies in Multiple Myeloma research. This includes the seminal study describing common mutation of NF-kB pathway genes in Multiple Myeloma, which was published in Cancer Cell. Importantly, Multiple Myeloma is yet another form of cancer, which disproportionately affects African Americans. Dr. Carpten’s laboratory led the first study to interrogate the somatic features of Multiple Myeloma tumors derived from African American patients, who have higher incidence rates and worse outcomes compared to European descent Myeloma patients (Blood).
Dr. Carpten has also been involved the development and application of high throughput genomic methods and technologies throughout his career. Currently, he has a major focus in Precision Medicine, where Next Generation Sequencing is being applied to interrogate the genomes and transcriptomes of tumors in a clinical setting to identify targetable events for select therapeutics (Molecular Cancer Therapeutics. 2013 Jan;12(1):104-16.) (PLoS Genetics. 2014 Feb 13;10(2):e1004135.). Towards these efforts, he coordinated the development of a CLIA-certified laboratory to support clinical genomic testing. This laboratory was later commercialized as Ashion Analytics, LLC.
Dr. Carpten has received research funding awards from various sources to support his research including NIH, Prostate Cancer Foundation, Susan G. Komen for the Cure, Multiple Myeloma Research Foundation, and a number of pharmaceutical companies. Dr. Carpten has co-authored over 160 publications in scientific journals that include Science, Nature, Nature Genetics, Genome Research, Cancer Research, Molecular Cancer Research, Cancer Cell, and the New England Journal of Medicine.
It is his hope that this work will one day lead to improvements in knowledge based therapeutics toward improvements in outcomes for cancer patients.